, - () , . . , . . . overlap- , , , .

: , , , overlap-, , , , .

: ... Overlap- : . Consilium Medicum. 2018; 12: 117-121.
 

(), , 1735%, (), 16,635,5%. , , overlap-, . , . . , - () , .

A.Ford ., 312 . 306 21% . ( 1,24; 95% 1,131,36), ( 1,25; 95% 1,121,40), , ( 1,59; 95% 1,271,99) ( 1,18; 95% 1,041,33). 20% (95% 16,324,8%). S.Kim . 10,3% ( 1,58; 95% 1,142,21) ( 1,45; 95% 1,012,07) , 60 ( 2,90; 95% 1,067,94) [1, 2].

I.Aziz . 6200 , () , , -, . , , . L.Eusebi ., 14 . , () . 44% (95% 35,152,9%), 6,94 (95% 4,3311,1%). 25,9% (95% 19,932,4%) [3, 4].

. 1840% . , III , IV 2016 .

, , . , , , . , , .

A.Sperber ., 288 . , , 35,5% . R.Chatila . 20,1% . , A.Althaus . 2400 , , 16,6% . ( 1,76; 95 % 1,342,31), ( 1,15; 95 % 1,071,23), ( 2,04; 95 % 1,542,70), ( 3,88; 95 % 3,214,68) ( 1,43; 95 % 1,041,99) [57].

, R.Yamamoto . 98 . , , 18,6%. . F.Klem ., 21 . 10 , 1 10,1% (95% 7,214,1) 14,5% (95% 7,725.5) 1 [8, 9].

N.De Bortoli . 700 . , 33% . M.Paudel ., 27,8% , . 7,1% , 5% , 5,7 2,1% [10, 11].

, . , , . , , , .

, , , , .

overlap-

, overlap-, , IV [12].

M.Von Wulffen . , , 64% . N.De Bortoli . 1215%. 79% 74% [13, 14].

A.Ford . , 23 500 , 239 . 27% (95% 2331%), 37% (95% 3045%). 8 (95% 5,7411,16). 2 15 42%. 8 . . , 100 . , S.Rasmussen . , 11,2, 7,7 10,5% , 2 30,7% 3 6,5%. , M.Kaji ., 2680 , 46,9% , 47,6% , 34,4% [1517].

, , , . .

. , , .

, , . , , overlap-, .. .

, , , . .

, . A.Shetty . 98,4% , 66,2%, 70,6%, 22,7% 10,9%. Y.Li . . , , [18, 19].

J.Matsuzaki ., , , . , , . S.Kim . , , , . 2 . ( 2,68; 95% 1,435,01) ( 2,21; 95% 1,144,30) . , , ( 3,88; 95% 1,838,19), ( 2,47; 95% 1,015,67) ( 2,84; 95% 1,395,82) . I.Hantoro . , [2022].

, A.Frandemark ., 500 , , , (R2 = 0,50; p< 0,05), - (R2 = 0,23; p< 0,05) (R2 = 0,38; p< 0,05). E.Hollister ., , , , , [23, 24].

, M.Kopczynska ., . , , , , . , . , I.Aziz ., K.Hulme ., [2527].

, . S.Lee . 200 () (), SF-36 (The Short Form-36): 59 72 , 53,2 73,1 . Z.Yi ., , , . , 80 76% 51,4 48,6% (p<0,05). , J.Vu . 900 , [2830].

, , . , , . , overlap- , , .

, , . , IV , .

, , . . , , , [31].

, , , , . , , , [32].

, , . , . ( ), (), ( ) , , . , , , [33, 34].

, , , STW5. . [35].

, , . , [36].

, (, ), (, ), 5- 3- (, , ), (), , , , , 1- () . , [37].

- (), ( ), , (, , ), (), , [38].

, , . , . . overlap-, , , .

A.Ford ., 8407 10 , ( 4,41; 99% 2,926,65), ( 1,77; 99% 1,282,46) ( 2,14; 99% 1,562,94) . , , . 32% . 29% 44% . ( 1,50; 99% 0,972,31) ( 1,09; 99% 1,011,17). , 20% , 17% , 43% [39].

C.Brujbu . , . , M.Levine . 16 , . (55%) (335 , 55% ) , , , . (p<0,01), (p>0,05). L.Marciani ., 30 , , [4042].

, , .

. , , , . .

, , .

, , .

, . overlap-, , , .

, , .

/References

1. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015; 64 (7): 104957. DOI: 10.1136/gutjnl-2014-307843
2. Kim SE, Kim N, Lee JY et al. Prevalence and Risk Factors of Functional Dyspepsia in Health Check-up Population: A Nationwide Multicenter Prospective Study. J Neurogastroenterol Motil 2018; 24 (4): 60313. DOI: 10.5056/jnm18068
3. Aziz I, Palsson OS, Tornblom H et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol 2018; 3 (4): 25262. DOI: 10.1016/S2468-1253(18)30003-7
4. Eusebi LH, Ratnakumaran R, Bazzoli F, Ford AC. Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16 (1): 3948.e1. DOI: 10.1016/j.cgh.2017.07.041
5. Sperber AD, Dumitrascu D, Fukudo S et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut 2017; 66 (6): 107582. DOI: 10.1136/gutjnl-2015-311240
6. Chatila R, Merhi M, Hariri E et al. Irritable bowel syndrome: prevalence, risk factors in an adult Lebanese population. BMC Gastroenterol 2017; 17 (1): 137. DOI: 10.1186/s12876-017-0698-2
7. Althaus A, Broicher W, Wittkamp P et al. Determinants and frequency of irritable bowel syndrome in a German sample. Z Gastroenterol 2016; 54 (3): 21725. DOI: 10.1055/s-0041-106856
8. Yamamoto R, Kaneita Y, Osaki Y et al. Irritable bowel syndrome among Japanese adolescents: A nationally representative survey. J Gastroenterol Hepatol 2015; 30 (9): 135460. DOI: 10.1111/jgh.12974
9. Klem F, Wadhwa A, Prokop LJ et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology 2017; 152 (5): 104254.e1. DOI: 10.1053/j.gastro.2016.12.039
10. De Bortoli N, Frazzoni L, Savarino EV et al. Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. Am J Gastroenterol 2016; 111 (12): 17117. DOI: 10.1038/ajg.2016.432
11. Paudel MS, Mandal AK, Shrestha B et al. Prevalence of Organic Colonic Lesions by Colonoscopy in Patients Fulfilling ROME IV Criteria of Irritable Bowel Syndrome. JNMA J Nepal Med Assoc 2018; 56 (209): 48792.
12. Drossman DA, Hasler WL et al. Rome-IV Functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016; 150 (6): 1257492.
13. Von Wulffen M, Talley NJ, Hammer J et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2018. DOI: 10.1007/s10620-018-5343-6
14. de Bortoli N, Tolone S, Frazzoni M et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018; 31 (6): 63948. DOI: 10.20524/aog.2018.0314
15. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8 (5): 4019. DOI: 10.1016/j.cgh.2009.07.020
16. Rasmussen S, Jensen TH, Henriksen SL et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol 2015; 50 (2): 1629. DOI: 10.3109/00365521.2014.983157
17. Kaji M, Fujiwara Y, Shiba M et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010; 25 (6): 11516. DOI: 10.1111/j.1440-1746.2010.06249.x
18. Shetty AJ, Balaraju G, Shetty S, Pai CG. Quality of life in dyspepsia and its subgroups using EQ-5D (EuroQol) questionnaire. Saudi J Gastroenterol 2017; 23 (2): 1126. DOI: 10.4103/sjg.SJG_487_16
19. Li Y, Gong Y, Li Y et al. Sleep disturbance and psychological distress are associated with functional dyspepsia based on Rome III criteria. BMC Psychiatry 2018; 18 (1): 133. DOI: 10.1186/s12888-018-1720-0
20. Matsuzaki J, Suzuki H, Togawa K et al. Burden of impaired sleep quality on work productivity in functional dyspepsia. United European Gastroenterol J 2018; 6 (3): 398406. DOI: 10.1177/2050640617726466
21. Kim SY, Choung RS, Lee SK et al. Self-reported Sleep Impairment in Functional Dyspepsia and Irritable Bowel Syndrome. J Neurogastroenterol Motil 2018; 24 (2): 2808. DOI: 10.5056/jnm17098
22. Hantoro IF, Syam AF. Measurement of Health-Related Quality of Life in Patients with Functional Dyspepsia. Acta Med Indones 2018; 50 (1): 8892.
23. Frandemark A, Tornblom H, Jakobsson S, Simren M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol 2018; 113 (10): 15409. DOI: 10.1038/s41395-018-0262-x
24. Hollister EB, Cain KC, Shulman RJ et al. Relationships of Microbiome Markers With Extraintestinal, Psychological Distress and Gastrointestinal Symptoms, and Quality of Life in Women With Irritable Bowel Syndrome. J Clin Gastroenterol 2018. DOI: 10.1097/MCG.0000000000001107
25. Kopczynska M, Mokros L, Pietras T, Malecka-Panas E. Quality of life and depression in patients with irritable bowel syndrome. Prz Gastroenterol 2018; 13 (2): 1028. DOI: 10.5114/pg.2018.75819
26. Aziz I, Tornblom H, Palsson OS et al. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. Am J Gastroenterol 2018; 113 (7): 101725. DOI: 10.1038/s41395-018-0074-z
27. Hulme K, Chilcot J, Smith MA. Doctor-patient relationship and quality of life in Irritable Bowel Syndrome: an exploratory study of the potential mediating role of illness perceptions and acceptance. Psychol Health Med 2018; 23 (6): 67484. DOI: 10.1080/13548506.2017.1417613
28. Lee SW, Chang CS, Lien HC et al. Impact of Overlapping Functional Gastrointestinal Disorders on the Presentation and Quality of Life of Patients with Erosive Esophagitis and Nonerosive Reflux Disease. Med Princ Pract 2015; 24 (5): 4915. DOI: 10.1159/000431370
29. Yi ZH, Yang ZB, Kang L et al. Clinical features, quality of life and psychological health of patients with irritable bowel syndrome and functional dyspepsia. Sichuan Da Xue Xue Bao Yi Xue Ban 2014; 45 (3): 4936.
30. Vu J, Kushnir V, Cassell B et al. The impact of psychiatric and extraintestinal comorbidity on quality of life and bowel symptom burden in functional GI disorders. Neurogastroenterol Motil 2014; 26 (9): 132332. DOI: 10.1111/nmo.12396
31. Van Oudenhove L, Crowell MD, Drossman DA et al. Biopsychosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2016. pii: S0016-5085(16)00218-3. DOI: 10.1053/j.gastro.2016.02.027.
32. Yamawaki H, Futagami S, Wakabayashi M et al. Management of functional dyspepsia: state of the art and emerging therapies. Ther Adv Chronic Dis 2018; 9 (1): 2332. DOI: 10.1177/2040622317725479
33. Drossman DA, Tack J, Ford AC et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology 2018; 154 (4): 114071.e1. DOI: 10.1053/j.gastro.2017.11.279
34. Pittayanon R, Yuan Y, Bollegala NP et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-analysis of Randomized Control Trials. Am J Gastroenterol 2018. DOI: 10.1038/s41395-018-0258-6
35. Tomita T, Oshima T, Miwa H. New Approaches to Diagnosis and Treatment of Functional Dyspepsia. Curr Gastroenterol Rep 2018; 20 (12): 55. DOI: 10.1007/s11894-018-0663-4
36. Camilleri M. Implications of Pharmacogenomics to the Management of IBS. Clin Gastroenterol Hepatol 2018. pii: S1542-3565(18)30458-0. DOI: 10.1016/j.cgh.2018.04.052
37. Nam Y, Min YS, Sohn UD. Recent advances in pharmacological research on the management of irritable bowel syndrome. Arch Pharm Res 2018; 41 (10): 95566. DOI: 10.1007/s12272-018-1068-5
38. Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018; 15 (10): 589605. DOI: 10.1038/s41575-018-0034-5
39. Ford AC, Forman D, Bailey AG et al. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther 2008; 28 (8): 101320. DOI: 10.1111/j.1365-2036.2008.03813.x
40. Brujbu C, Macovei A. Clinical, epidemiological and prophylactic aspects of dyspepsia. Rev Med Chir Soc Med Nat Iasi 2014; 118 (1): 1416.
41. Levine ME, Koch SY, Koch KL. Lipase Supplementation before a High-Fat Meal Reduces Perceptions of Fullness in Healthy Subjects. Gut Liver 2015; 9 (4): 4649. DOI: 10.5009/gnl14005
42. Marciani L, Cox EF, Pritchard SE et al. Additive effects of gastric volumes and macronutrient composition on the sensation of postprandial fullness in humans. Eur J Clin Nutr 2015; 69 (3): 3804. DOI: 10.1038/ejcn.2014.194